Oct 12, 2021 / 08:30PM GMT
Thomas Yip - H.C. Wainwright - Analyst
Hello, everyone. Welcome to the H.C. Wainwright 5th Annual NASH Conference. For our next presentation, we have Dr. Christian Marsolais, Chief Medical Officer of Theratechnologies, a commercial stage company specializing in therapeutics of NASH, oncology and HIV. Dr. Marsolais, very good to have you with us. Please go ahead with your presentation.
Christian Marsolais - Theratechnologies Inc. - SVP & CMO
Thank you very much, Thomas. Good afternoon, everyone. My name is Christian Marsolais, and I'm the Chief Medical Officer at Theratechnologies, and I will be presenting today the use of tesamorelin and for the treatment of NASH during this presentation. First, I would like to thank the H.C. Wainwright organization for inviting Theratechnologies to present our data at this 5th Annual NASH Investor Conference. I will give you a minute to read our forward-looking information.
I know that it has been a long day for you and I appreciate that you can sit with us for an additional 20 minutes just before Dr. Loomba starts
Theratechnologies Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot